Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert

Li, Xiaoqi; Gulati, Mansi; Larson, Alaina C.; Solheim, Joyce C.; Jain, Maneesh; Kumar, Sushil; Batra, Surinder K.

doi:10.1016/j.semcancer.2022.08.009

Cited by 25 publications

(19 citation statements)

References 162 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The infinite proliferation of tumor cells requires continuous shaping of a suitable microenvironment outside the tumor (36). Cancer invasion and distant metastasis are attributed to inflammatory factors in the tumor microenvironment, macrophagedriven chronic low-grade inflammation is an important feature of cancer (37,38). However, the activated inflammatory response can induce the pyroptosis, an inflammatory cell death, which has been shown to be a more effective immunotherapy approach with fewer side effects compared with conventional immunotherapy, providing a great opportunity in treating solid tumors (17, 39).…”

Section: Discussionmentioning

confidence: 99%

Knocking down GALNT6 promotes pyroptosis of pancreatic ductal adenocarcinoma cells through NF-κB/NLRP3/GSDMD and GSDME signaling pathway

Ding

Liu²,

Lv³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundPancreatic ductal adenocarcinoma (PDAC), the most prevalent type of pancreatic cancer, is a highly lethal malignancy with poor prognosis. Polypeptide N-acetylgalactosaminyltransferase-6 (GALNT6) is frequently overexpressed in PDAC. However, the role of GALNT6 in the PDAC remains unclear.MethodsThe expression of GALNT6 in pancreatic cancer and normal tissues were analyzed by bioinformatic analyses and immunohistochemistry. CCK8 and colony formation were used to detect cell proliferation. Flow cytometry was applied to detect cell cycle.The pyroptosis was detected by scanning electron microscopy. The mRNA expression was detected by qRT-PCR. The protein expression and localization were detected by western blot and immunofluorescence assay. ELISA was used to detect the levels of inflammatory factors.ResultsThe expression of GALNT6 was associated with advanced tumor stage, and had an area under curve (AUC) value of 0.919 in pancreatic cancer based on the cancer genome atlas (TCGA) dataset. Knockdown of GALNT6 inhibited cell proliferation, migration, invasion and cell cycle arrest of PDAC cells. Meanwhile, knockdown of GALNT6 increased the expression levels of interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and interleukin-18 (IL-18), the release of inflammasome and an increasing of Gasdermin D (GSDMD), N-terminal of GSDMD (GSDMD-N), Gasdermin E (GSDME) and N-terminal of GSDME (GSDME-N) in PDAC cells. GALNT6 suppressed the expression of NOD-like receptor thermal protein domain associated protein 3 (NLRP3) and GSDMD by glycosylation of NF-κB and inhibiting the nucleus localization of NF-κB. Additionally, GALNT6 promotes the degradation of GSDME by O-glycosylation.ConclusionWe found that GALNT6 is highly expressed in pancreatic cancer and plays a carcinogenic role. The results suggested that GALNT6 regulates the pyroptosis of PDAC cells through NF-κB/NLRP3/GSDMD and GSDME signaling. Our study might provides novel insights into the roles of GALNT6 in PDAC progression.

show abstract

Section: Discussionmentioning

confidence: 99%

Knocking down GALNT6 promotes pyroptosis of pancreatic ductal adenocarcinoma cells through NF-κB/NLRP3/GSDMD and GSDME signaling pathway

Ding

Liu²,

Lv³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Immunotherapy with immune checkpoint inhibitors (ICIs) has shown promising results in cancer treatment [26]. However, it was found that targeting PD-1 alone was not successful in pancreatic cancer, and as the study progressed another checkpoint molecule, VISTA, could improve macrophage function to exert anti-cancer effects in pancreatic cancer [27,28].…”

Section: Discussionmentioning

confidence: 99%

BCL2L1 is regulated by the lncRNA MIR4435-2HG-miR-513a-5p-BCL2L1 ceRNA axis and serves as a biomarker for pancreatic adenocarcinoma treatment and prognosis

Zhu,

Chen,

Bai

et al. 2023

Preprint

View full text Add to dashboard Cite

Pancreatic adenocarcinoma (PAAD) is one of the most malignant cancers. After escaping death, cancer cells are made more metastatic, aggressive, and also drug-resistant through anoikis resistance. The aim of this study is to explore the molecular mechanisms of anoikis-related genes in PAAD and to identify potential key biomarkers. We integrated information about PAAD from The Cancer Genome Atlas (TCGA) and The Genotype-Tissue Expression (GTEx) databases and identified anoikis-related gene BCL2L1 by survival analysis, univariate Cox regression analysis, and multifactorial Cox regression analysis. Various bioinformatics approaches showed that BCL2L1 was a valuable prognostic marker that might be involved in PAAD development and progression through different mechanisms, including cancer intervention, genomic heterogeneity, and RNA modifications. Our analysis showed that BCL2L1 expression also closely correlates with the expression of various immune checkpoint inhibitors. In particular, we found that long non-coding RNA MIR4435-2HG acted as ceRNA sponging miR-513a-5p to promote the expression of BCL2L1, thereby promoting pancreatic cancer cells proliferation. In conclusion, BCL2L1 expression regulated by the MIR4435-2HG-miR-513a-5p-BCL2L1 ceRNA axis might be used as a biomarker for cancer prognosis, treatment selection, and follow-up in PAAD patients.

show abstract

“…Among the specialized domains within the TME, hypoxic regions and the immune microenvironment are particularly critical. These niches possess the capacity to profoundly reprogram cancer cell biology and are thus considered promising targets for therapeutic intervention, notably in the realms of targeted therapy and immunotherapy 217,218 . Recent discoveries have underscored the role of epigenetic modifications as a means by which cancer cells modulate immunosuppression and advance disease progression within the TME.…”

Section: Epigenetic Alterations In Cancermentioning

confidence: 99%

Epigenetic regulation in cancer

Gu,

Ren,

Fang

et al. 2024

MedComm

View full text Add to dashboard Cite

Epigenetic modifications are defined as heritable changes in gene activity that do not involve changes in the underlying DNA sequence. The oncogenic process is driven by the accumulation of alterations that impact genome's structure and function. Genetic mutations, which directly disrupt the DNA sequence, are complemented by epigenetic modifications that modulate gene expression, thereby facilitating the acquisition of malignant characteristics. Principals among these epigenetic changes are shifts in DNA methylation and histone mark patterns, which promote tumor development and metastasis. Notably, the reversible nature of epigenetic alterations, as opposed to the permanence of genetic changes, positions the epigenetic machinery as a prime target in the discovery of novel therapeutics. Our review delves into the complexities of epigenetic regulation, exploring its profound effects on tumor initiation, metastatic behavior, metabolic pathways, and the tumor microenvironment. We place a particular emphasis on the dysregulation at each level of epigenetic modulation, including but not limited to, the aberrations in enzymes responsible for DNA methylation and histone modification, subunit loss or fusions in chromatin remodeling complexes, and the disturbances in higher‐order chromatin structure. Finally, we also evaluate therapeutic approaches that leverage the growing understanding of chromatin dysregulation, offering new avenues for cancer treatment.

show abstract

Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert

Cited by 25 publications

References 162 publications

Knocking down GALNT6 promotes pyroptosis of pancreatic ductal adenocarcinoma cells through NF-κB/NLRP3/GSDMD and GSDME signaling pathway

Knocking down GALNT6 promotes pyroptosis of pancreatic ductal adenocarcinoma cells through NF-κB/NLRP3/GSDMD and GSDME signaling pathway

BCL2L1 is regulated by the lncRNA MIR4435-2HG-miR-513a-5p-BCL2L1 ceRNA axis and serves as a biomarker for pancreatic adenocarcinoma treatment and prognosis

Epigenetic regulation in cancer

Contact Info

Product

Resources

About